A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: A kinetic prospective study

Journal of Viral Hepatitis

Volumn 16, Issue 7, 2009, Pages 500-505

  Deltenre, P ^a,b   Canva, V ^a   Nady, M El ^a   Francois C ^c   Castelain, S ^c   Dharancy, S ^a,d   Louvet, A ^a,d   Bocket, L ^e   Lazrek, M ^e   Hollebecque, A ^a,d   Wartel, F ^a   Henrion, J ^b   Duverlie, G ^c   Mathurin, P ^a,d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Hospital de Jolimont   (Belgium)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e Centre de Biologie Pathologie   (France)

Author keywords

Antiviral therapy; Hepatitis C; Sustained virological response; Viral kinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 67650465746     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01100.x     Document Type: Article

References (19)

1. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004 36 : 646 654. (Pubitemid 41115431)
2. Puoti C, Magrini A, Stati T et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997 26 : 1393 1398. (Pubitemid 27520001)
3. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003 38 : 511 517. (Pubitemid 36399256)
4. Shiffman ML, Diago M, Tran A et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006 4 : 645 652.
5. Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998 27 : 868 872. (Pubitemid 28103567)
6. Pradat P, Alberti A, Poynard T et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002 36 : 973 977.
7. Okanoue T, Makiyama A, Nakayama M et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005 43 : 599 605. (Pubitemid 41253226)
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
9. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965. (Pubitemid 32913521)
10. Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004 127 : 1724 1732. (Pubitemid 39575851)
11. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003 37 : 1351 1358. (Pubitemid 36667315)
12. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004 40 : 1442 1449. (Pubitemid 39657020)
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652. (Pubitemid 37052151)
14. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005 43 : 425 433. (Pubitemid 41111423)
15. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 43 : 954 960. (Pubitemid 43724620)
16. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44 : 97 103. (Pubitemid 41772522)
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C Hepatology 1994 20 : 15 20.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293. (Pubitemid 26260021)
19. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York : ed. J.W.A. Sons, 2002.